Adult Cancers Breast (24 trials) Cutaneous (13 trials) Gastrointestinal (15 trials) Genitourinary (29 trials) Gynecological (5 trials) Head and Neck (7 trials) Malignant Hematology (31 trials) Multiple / Ill-Defined Disease Sites (14 trials) Neurologic Oncology (8 trials) Thoracic (12 trials) Other Trials (92 trials) Total Trials = 250 Adult Interventional Trials May 2021 UCSF Protocol ClinicalTrials.gov PI Name Title Protocol Type Study Contact No. Protocol Breast > Prevention 16752 NCT02620852 Esserman, Laura The WISDOM Study (Women Informed to Screen Depending on Measures of Risk) Screening [email protected] Breast > Breast Cancer Treatment > Advanced Breast Cancer 187523 NCT03344965 Melisko, Michelle A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline Treatment [email protected] or Somatic Mutations in DNA Repair Genes "Olaparib Expanded" EA-RUGO- NCT04395508 Rugo, Hope EXPANDED ACCESS, SINGLE-ARM, MULTICENTER STUDY TO PROVIDE AT HOME Other [email protected] 5142020 SUBCUTANEOUS ADMINISTRATION OF PERTUZUMAB AND TRASTUZUMAB FIXED-DOSE COMBINATION (PH FDC SC) FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER DURING THE COVID-19 PANDEMIC Breast > Breast Cancer Treatment > Early Stage Breast Cancer 167514 NCT03094052 Chien, Jo An open label study to characterize the incidence and severity of diarrhea in patients with Treatment [email protected] HER2+ breast cancer treated with neratinib with or without trastuzumab 16704 NCT02872025 Esserman, Laura Testing the Ability of Pembrolizumab and mRNA 2752 to Alter the Tumor Immune Treatment [email protected]; MicroEnvironment (TIME) of High Risk DCIS [email protected] 19753 NCT03562637 Melisko, Michelle The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Treatment [email protected] Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer Breast > Breast Cancer Treatment > Radiation 117515 NCT01570998 Alvarado, Michael Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Treatment [email protected]; Registry Trial of Targeted Intraoperative Radiation Therapy following Breast-Conserving [email protected] Surgery last updated 5/3/2021 Page 2 Adult Interventional Trials May 2021 UCSF Protocol ClinicalTrials.gov PI Name Title Protocol Type Study Contact No. Protocol Breast > Breast Cancer Treatment > Advanced Breast Cancer > ER+ 19754 NCT03858972 Rugo, Hope Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Treatment [email protected] Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane 20757 NCT04305496 Rugo, Hope A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Treatment [email protected] + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291) 197511 NCT03781063 Rugo, Hope An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative Treatment [email protected] to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation 187526 NCT03250676 Munster, Pamela A Phase I-II multicenter, open label trial of H3B-6545, a covalent antagonist of estrogen receptor Treatment [email protected] alpha, in women with locally advanced or metastatic estrogen receptor-positive, HER2 negative breast cancer 18751 NCT03326102 Melisko, Michelle A Multi-center, Open-Label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Treatment [email protected] Pharmacokinetics of DHP107 (Liporaxel, Oral Paclitaxel) Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer 197520 NCT04190056 Munster, Pamela Epigenetic priming for Immune therapy in ER-positive breast cancer in biomarker select Treatment [email protected] population 157521 NCT03095352 Rugo, Hope A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Treatment [email protected] Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease Breast > Breast Cancer Treatment > Advanced Breast Cancer > HER2+ 157521 NCT03095352 Rugo, Hope A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Treatment [email protected] Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease 197516 NCT04042701 Rugo, Hope A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), Treatment [email protected] An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, In Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC) 20754 NCT03975647 Chien, Jo Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado- Treatment [email protected] trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer(HER2CLIMB-02) Breast > Breast Cancer Treatment > Early Stage Breast Cancer > Invasive 187513 NCT03422003 Park, Catherine Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) Supportive Care 1-877-827-3222 for Invasive Breast Carcinoma last updated 5/3/2021 Page 3 Adult Interventional Trials May 2021 UCSF Protocol ClinicalTrials.gov PI Name Title Protocol Type Study Contact No. Protocol Breast > Breast Cancer Treatment > Advanced Breast Cancer > Triple Negative 207516 NCT04461600 Rugo, Hope TENACITY: A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Treatment [email protected] Patients with Notch-activated Triple Negative Breast Cancer 199516 NCT03829436 Munster, Pamela A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Treatment 1-877-827-3222 Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors 197525 NCT04191135 Rugo, Hope An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Treatment [email protected] Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009) 157521 NCT03095352 Rugo, Hope A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Treatment [email protected] Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease Breast > Breast Cancer Treatment > Advanced Breast Cancer > Brain Metastases/leptomeningeal dz 197515 NCT03501979 Melisko, Michelle A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Treatment [email protected] Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer 17752 NCT02915744 Melisko, Michelle A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Treatment [email protected] Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine Breast > Breast Cancer Treatment > Early Stage Breast Cancer > Invasive > Neoadjuvant 097517 NCT01042379 Chien, Jo I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Treatment [email protected]; Imaging and Molecular Analysis 2) [email protected]; [email protected] 177539 NCT02206984 Mukhtar, Rita A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer Treatment [email protected] last updated 5/3/2021 Page 4 Adult Interventional Trials May 2021 UCSF Protocol ClinicalTrials.gov PI Name Title Protocol Type Study Contact No. Protocol Cutaneous > Melanoma 18859 NCT03820986 Daud, Adil A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Treatment [email protected] Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003) 20863 NCT04598009 Tsai, Katy A phase II study of binimetinib in combination with imatinib in patients with advanced KIT-mutant Treatment [email protected] melanoma 19854 NCT03684785 Daud, Adil A Phase 1b/2 Study of Cavrotolimod Combined with Pembrolizumab or Cemiplimab in Patients Treatment [email protected] with Advanced Solid Tumors 19855 NCT04135352 Daud, Adil A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of V938 in Treatment [email protected] Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic or Recurrent Malignancies 18851 NCT03132675 Tsai, Katy A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation in Treatment [email protected]; Combination With Intravenous Pembrolizumab in